Vincerx Pharma Statistics
Total Valuation
Vincerx Pharma has a market cap or net worth of $19.20 million. The enterprise value is $8.85 million.
| Market Cap | 19.20M |
| Enterprise Value | 8.85M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Vincerx Pharma has 21.41 million shares outstanding. The number of shares has increased by 1.26% in one year.
| Shares Outstanding | 21.41M |
| Shares Change (YoY) | +1.26% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 25.20% |
| Owned by Institutions (%) | 40.82% |
| Float | 17.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.71 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.63, with a Debt / Equity ratio of 0.22.
| Current Ratio | 2.63 |
| Quick Ratio | 2.48 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -187.70% and return on invested capital (ROIC) is -310.47%.
| Return on Equity (ROE) | -187.70% |
| Return on Assets (ROA) | -126.30% |
| Return on Capital (ROIC) | -310.47% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$956,119 |
| Employee Count | 42 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.10% in the last 52 weeks. The beta is 0.81, so Vincerx Pharma's price volatility has been lower than the market average.
| Beta (1Y) | 0.81 |
| 52-Week Price Change | -27.10% |
| 50-Day Moving Average | 4.03 |
| 200-Day Moving Average | 1.73 |
| Relative Strength Index (RSI) | 31.20 |
| Average Volume (30 Days) | 1,159,501 |
Short Selling Information
The latest short interest is 1.20 million, so 5.59% of the outstanding shares have been sold short.
| Short Interest | 1.20M |
| Short Previous Month | 799,873 |
| Short % of Shares Out | 5.59% |
| Short % of Float | 6.79% |
| Short Ratio (days to cover) | 0.72 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.61M |
| Pretax Income | -40.16M |
| Net Income | -40.16M |
| EBITDA | -39.24M |
| EBIT | -40.16M |
| Earnings Per Share (EPS) | -$1.89 |
Balance Sheet
The company has $12.85 million in cash and $2.50 million in debt, giving a net cash position of $10.35 million or $0.48 per share.
| Cash & Cash Equivalents | 12.85M |
| Total Debt | 2.50M |
| Net Cash | 10.35M |
| Net Cash Per Share | $0.48 |
| Equity / Book Value | 11.22M |
| Book Value Per Share | 0.52 |
| Working Capital | 9.13M |
Cash Flow
| Operating Cash Flow | -40.45M |
| Capital Expenditures | n/a |
| Free Cash Flow | -40.45M |
| FCF Per Share | -$1.90 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vincerx Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.26% |
| Shareholder Yield | -1.26% |
| Earnings Yield | -209.14% |
| FCF Yield | -210.68% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -16.77% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |